

Appl. No. 09/744,441

AMENDMENTS TO THE CLAIMS

1. **(Currently Amended)** An isolated antagonist of ~~the~~ a ligand of the Corticotropin-Releasing Factor Receptor, type 2 (CRFR2) lacking the 8 to 10 N-terminal amino acids of native sauvagine and comprising the amino acid sequence Xaa₁-Xaa₂-Leu-Leu-Arg-Lys-Met-Ile-Glu-Ile-Glu-Lys-Gln-Glu-Lys-Glu-Lys-Gln-Gln-Ala-Ala-Asn-Asn-Arg-Leu-Leu-Leu-Asp-Thr-Ile-NH₂, wherein Xaa₁ is a neutral amino acid, and Xaa₂ is a charged amino acid.
2. **(Currently Amended)** The isolated antagonist of claim 1 lacking the 10 N-terminal amino acids of native sauvagine.
3. **Canceled**
4. **(Currently Amended)** The isolated antagonist of claim 3~~1~~, wherein Xaa₁ is a hydrophobic amino acid, and Xaa₂ is Glu or His.
5. **(Currently Amended)** The isolated antagonist of claim 4, wherein Xaa₁ is Leu.
6. **(Currently Amended)** The isolated antagonist of claim 3~~1~~, wherein Xaa₁ is a polar amino acid, and Xaa₂ is Glu or His.
7. **(Currently Amended)** The isolated antagonist of claim 6, wherein Xaa₁ is Tyr.
8. **(Currently Amended)** The isolated antagonist of claim 3~~1~~, wherein Xaa₁ is in the D-configuration.
9. **(Currently Amended)** The isolated antagonist of claim 8, wherein Xaa₁ is D-Leu.
10. **(Currently Amended)** The isolated antagonist of claim 8, wherein Xaa₁ is D-Tyr.

Appl. No. 09/744,441

11. **(Currently Amended)** The isolated antagonist of claim 5, wherein Xaa₂ is Glu.
12. **(Currently Amended)** The isolated antagonist of claim 8, wherein Xaa₁ is D-Phe.
13. **(Currently Amended)** The isolated antagonist of claim 7, wherein Xaa₂ is His.
14. **(Currently Amended)** An isolated antagonist of the a ligand of the Corticotropin-Releasing Factor Receptor, type 2 (CRFR2) lacking the 11 N-terminal amino acid of native sauvagine, wherein the N-terminal amino acid-acids of said antagonist is a charged amino acid and comprising the amino acid sequence Xaa₁-Xaa₂-Leu-Leu-Arg-Lys-Met-Ile-Glu-Ile-Glu-Lys-Gln-Glu-Lys-Glu-Lys-Gln-Gln-Ala-Ala-Asn-Asn-Arg-Leu-Leu-Leu-Asp-Thr-Ile-NH₂, wherein Xaa₁ is a neutral amino acid, and Xaa₂ is a charged amino acid.
15. **(Currently Amended)** The isolated antagonist of claim 14, wherein said charged amino acid is positively charged.
16. **(Currently Amended)** The isolated antagonist of claim 15, wherein said charged amino acid is His.
17. **(Currently Amended)** The isolated antagonist of claim 14 which comprises a phenyldiazirine group coupled to the N-terminal amino acid of said antagonist.
18. **(Currently Amended)** The isolated antagonist of claim 17, wherein said phenyldiazirine group is a 4-(1-azi-2,2,2-trifluoroethyl)benzoyl (ATB)-group.
19. **Canceled**
20. **Canceled**

Appl. No. 09/744,441

21. **Canceled**
22. **Canceled**
23. **Canceled**
24. **Canceled**
25. **Canceled**
26. **Canceled**
27. **(Currently Amended)** A pharmaceutical composition comprising the antagonist of claim 1, ~~the polynucleotide of claim 19, the vector of claim 20, the antibody of claim 25 and/or the anti-idiotypic antibody of claim 26~~ and optionally a pharmaceutically acceptable carrier and/or diluent.
28. **Canceled**
29. **(Currently Amended)** A kit comprising
(a) — an antagonist of claim 1;
(b) — ~~the polynucleotide of claim 19;~~
(c) — ~~the vector of claim 20;~~
(d) — ~~the antibody of claim 25; and/or~~
(e) — ~~the anti-idiotypic antibody of claim 26.~~
30. **Canceled**
31. **(Previously Presented)** The antagonist of claim 1, wherein said CRFR2 is CRFR2 α or CRFR2 β .

AUG. 2. 2004 1:39PM BSKB COM

NO. 2767 P. 8

Appl. No. 09/744,441

32. **Canceled**

33. **Canceled**